PTC Therapeutics (BH3) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BH3 Analyst Ratings

Moderate Buy

8 Buy

1 Hold

1 Sell

Based on 10 analysts giving stock ratings to

PTC

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BH3 Stock 12 Month Forecast

Average Price Target

€87.41

▲(43.81% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is €87.41 with a high forecast of €119.51 and a low forecast of €61.06. The average price target represents a 43.81% change from the last price of €60.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","60":"€60","80":"€80","100":"€100","120":"€120"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":119.50787151,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€119.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.406487046,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€87.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.0624161,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€61.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,60,80,100,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.26,64.8175285776923,69.37505715538461,73.93258573307692,78.49011431076923,83.04764288846154,87.60517146615385,92.16270004384614,96.72022862153847,101.27775719923076,105.83528577692309,110.39281435461538,114.95034293230769,{"y":119.50787151,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.26,62.348191311230764,64.43638262246154,66.52457393369231,68.61276524492307,70.70095655615384,72.78914786738461,74.87733917861539,76.96553048984615,79.05372180107692,81.14191311230769,83.23010442353845,85.31829573476922,{"y":87.406487046,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.26,60.321724315384614,60.38344863076923,60.445172946153846,60.50689726153846,60.56862157692308,60.630345892307695,60.6920702076923,60.75379452307692,60.815518838461536,60.87724315384615,60.93896746923077,61.000691784615384,{"y":61.0624161,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.16,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.26,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€119.51

Average Price Target€87.41

Lowest Price Target€61.06

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kristen Kluska

Cantor Fitzgerald

€113.4→€119.51

Buy

96.62%

Upside

Assigned

09/21/26

Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), NewAmsterdam Pharma Company (NAMS)

Basma Radwan

Leerink Partners

€61.06→€85.49

Buy

40.65%

Upside

Initiated

09/14/26

PTC Therapeutics upgraded to Outperform from Market Perform at LeerinkPTC Therapeutics upgraded to Outperform from Market Perform at Leerink

Benjamin Burnett

Wells Fargo

€95.08

Buy

56.44%

Upside

Reiterated

09/02/26

Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

Joseph Thome

TD Cowen

€78.51

Buy

29.17%

Upside

Reiterated

08/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Abbott Laboratories (NYSE: ABT), PTC Therapeutics (NASDAQ: PTCT) and Ansell (Other OTC: ANSLF)

Tazeen Ahmad

Bank of America Securities

€83.74

Buy

37.78%

Upside

Reiterated

08/13/26

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

Eliana Merle

Barclays

€104.68→€106.42

Buy

75.10%

Upside

Reiterated

08/13/26

Barclays Sticks to Their Buy Rating for PTC Therapeutics (PTCT)

Judah Frommer

Morgan Stanley

€81.13→€90.72

Buy

49.26%

Upside

Reiterated

07/31/26

Morgan Stanley Keeps Their Buy Rating on PTC Therapeutics (PTCT)

Brian Abrahams

RBC Capital

€74.15

Hold

21.99%

Upside

Reiterated

07/30/26

PTC Therapeutics (PTCT) Gets a Hold from RBC Capital

Paul Choi

Goldman Sachs

€61.06

Sell

0.46%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Regeneron (NASDAQ: REGN) and PTC Therapeutics (NASDAQ: PTCT)

Brian Cheng

J.P. Morgan

€77.64→€79.38

Buy

30.60%

Upside

Reiterated

07/13/26

PTC Therapeutics price target raised to $91 from $89 at JPMorganPTC Therapeutics price target raised to $91 from $89 at JPMorgan

Eric Joseph

Citi

€65.42→€94.21

Buy

55.00%

Upside

Initiated

06/10/26

PTC Therapeutics assumed with Buy from Neutral at CitiPTC Therapeutics assumed with Buy from Neutral at Citi

Faisal Khurshid

Jefferies

€66.3→€74.15

Buy

21.99%

Upside

Upgraded

05/27/26

PTC Therapeutics upgraded to Buy from Hold at JefferiesPTC Therapeutics upgraded to Buy from Hold at Jefferies

Tiago Fauth

Raymond James

€75.02→€82.87

Buy

36.34%

Upside

Reiterated

05/08/26

PTC Therapeutics (PTCT) Gets a Buy from Raymond James

Joon Lee

Truist Financial

―

Buy

―

Reiterated

02/27/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE)

Sami Corwin

William Blair

―

Buy

―

Reiterated

02/20/26

PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kristen Kluska

Cantor Fitzgerald

€113.4→€119.51

Buy

96.62%

Upside

Assigned

09/21/26

Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), NewAmsterdam Pharma Company (NAMS)

Basma Radwan

Leerink Partners

€61.06→€85.49

Buy

40.65%

Upside

Initiated

09/14/26

PTC Therapeutics upgraded to Outperform from Market Perform at LeerinkPTC Therapeutics upgraded to Outperform from Market Perform at Leerink

Benjamin Burnett

Wells Fargo

€95.08

Buy

56.44%

Upside

Reiterated

09/02/26

Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

Joseph Thome

TD Cowen

€78.51

Buy

29.17%

Upside

Reiterated

08/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Abbott Laboratories (NYSE: ABT), PTC Therapeutics (NASDAQ: PTCT) and Ansell (Other OTC: ANSLF)

Tazeen Ahmad

Bank of America Securities

€83.74

Buy

37.78%

Upside

Reiterated

08/13/26

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

Eliana Merle

Barclays

€104.68→€106.42

Buy

75.10%

Upside

Reiterated

08/13/26

Barclays Sticks to Their Buy Rating for PTC Therapeutics (PTCT)

Judah Frommer

Morgan Stanley

€81.13→€90.72

Buy

49.26%

Upside

Reiterated

07/31/26

Morgan Stanley Keeps Their Buy Rating on PTC Therapeutics (PTCT)

Brian Abrahams

RBC Capital

€74.15

Hold

21.99%

Upside

Reiterated

07/30/26

PTC Therapeutics (PTCT) Gets a Hold from RBC Capital

Paul Choi

Goldman Sachs

€61.06

Sell

0.46%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Regeneron (NASDAQ: REGN) and PTC Therapeutics (NASDAQ: PTCT)

Brian Cheng

J.P. Morgan

€77.64→€79.38

Buy

30.60%

Upside

Reiterated

07/13/26

PTC Therapeutics price target raised to $91 from $89 at JPMorganPTC Therapeutics price target raised to $91 from $89 at JPMorgan

Eric Joseph

Citi

€65.42→€94.21

Buy

55.00%

Upside

Initiated

06/10/26

PTC Therapeutics assumed with Buy from Neutral at CitiPTC Therapeutics assumed with Buy from Neutral at Citi

Faisal Khurshid

Jefferies

€66.3→€74.15

Buy

21.99%

Upside

Upgraded

05/27/26

PTC Therapeutics upgraded to Buy from Hold at JefferiesPTC Therapeutics upgraded to Buy from Hold at Jefferies

Tiago Fauth

Raymond James

€75.02→€82.87

Buy

36.34%

Upside

Reiterated

05/08/26

PTC Therapeutics (PTCT) Gets a Buy from Raymond James

Joon Lee

Truist Financial

―

Buy

―

Reiterated

02/27/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE)

Sami Corwin

William Blair

―

Buy

―

Reiterated

02/20/26

PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

LFMDLifeMD

ORKAOruka Therapeutics

ACHVAchieve Life Sciences

PLSEPulse Biosciences

PMNProMIS Neurosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PTC Therapeutics

3 Months

Tiago FauthRaymond James

Success Rate

13/17 ratings generated profit

Average Return

+16.06%

Copying Tiago Fauth's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +16.06% per trade.

1 Year

Tiago FauthRaymond James

Success Rate

15/17 ratings generated profit

Average Return

+50.01%

Copying Tiago Fauth's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +50.01% per trade.

2 Years

Tiago FauthRaymond James

Success Rate

15/17 ratings generated profit

Average Return

+75.09%

Copying Tiago Fauth's trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +75.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BH3 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BH3 has received 21 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. BH3 average Analyst price target in the past 3 months is 87.41.

Each month's total comprises the sum of three months' worth of ratings.

BH3 Financial Forecast

BH3 Earnings Forecast

Next quarter’s earnings estimate for BH3 is €0.25 with a range of -€0.78 to €0.83. The previous quarter’s EPS was €0.79. BH3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BH3 has Performed in-line its overall industry.

BH3 Sales Forecast

Next quarter’s sales forecast for BH3 is €262.32M with a range of €236.22M to €277.99M. The previous quarter’s sales results were €311.15M. BH3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BH3 has Performed in-line its overall industry.

BH3 Stock Forecast FAQ

What is DE:BH3’s average 12-month price target, according to analysts?

Based on analyst ratings, PTC Therapeutics’s 12-month average price target is 87.41.

What is DE:BH3’s upside potential, based on the analysts’ average price target?

PTC Therapeutics has 43.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTC Therapeutics a Buy, Sell or Hold?

PTC Therapeutics has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 1 hold ratings and 1 sell ratings.

What is PTC Therapeutics’s share price target?

The average share price target for PTC Therapeutics is 87.41. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €119.51 ,and the lowest forecast is €61.06. The average share price target represents 43.81% Increase from the current price of €60.78.

What do analysts say about PTC Therapeutics?

PTC Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of PTC Therapeutics?

To buy shares of DE:BH3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

PTC Therapeutics (BH3) Stock Forecast & Price Target

BH3 Analyst Ratings

BH3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering PTC Therapeutics

BH3 Analyst Recommendation Trends

BH3 Financial Forecast

BH3 Earnings Forecast

BH3 Sales Forecast

BH3 Stock Forecast FAQ

Detailed List of Analyst Forecasts